Alto Neuroscience Business Summary

Alto Neuroscience, Inc. (ANRO) is a clinical-stage biopharmaceutical company that utilizes its proprietary Precision Psychiatry Platform™ to develop personalized therapies for neuropsychiatric conditions. As a pre-revenue biotechnology firm, its business model is predicated on the clinical advancement and eventual commercialization or strategic out-licensing of its targeted drug candidates, including ALTO-100, ALTO-101, ALTO-207, and ALTO-300. The company’s primary business segments are organized around its biomarker-driven pipeline targeting Major Depressive Disorder (MDD), schizophrenia, and bipolar depression, where it employs AI-driven analysis of EEG, genetics, and neurocognitive data to stratify patient populations. Alto competes directly with CNS-focused innovators such as Neumora Therapeutics, Praxis Precision Medicines, and Relmada Therapeutics. Within the competitive landscape, Alto is positioned as a first-mover in "precision psychiatry," aiming to disrupt the traditional trial-and-error treatment paradigm by matching patients to medications based on specific neurobiological profiles. The company was founded by Dr. Amit Etkin, who serves as President, CEO, and Chairman, following a distinguished career as a tenured professor at Stanford University. The executive leadership team includes Chief Financial Officer and Chief Business Officer Nick Smith, Chief Operating Officer Michael Hanley, Chief Medical Officer Dr. Adam Savitz, and Co-Founder and Chief Data Science Officer Wei Wu. Alto’s strategic direction is further guided by a board of directors that includes prominent industry figures such as Dr. Husseini Manji and Dr. Raymond Sanchez. The firm has attracted significant capital from high-profile investors including Alkeon Capital Management, Point72, and Apeiron Investment Group. As of February 2026, Alto maintains a robust financial position with a cash runway extending into 2028, supported by a $50 million private placement completed in late 2025 to accelerate its late-stage clinical readouts.